This was a month that will likely be remembered as when Takeda and Shire shook hands on a $62 billion deal for the Japanese drugmaker to take over the rare diseases specialist.
If the deal goes through — and there are still a few obstacles to be overcome Takeda shareholders will own around 50% of the combined group.
There were also a couple of other acquisitions worth more than $1 billion, with two big pharma players adding to their assets in the immuno-oncology space and a merger creating the leading player in the Australian generics market.
The table below details the deals announced.
Company | Takeover candidate | Value | Why? |
---|---|---|---|
Janssen | BeneVir | $1.04 billion | To add BeneVir’s oncolytic immunotherapy platform to Janssen’s immuno-oncology efforts |
Takeda | Shire | $62 billion | To create a combined group that is a global, values-based, R&D-driven biopharmaceutical leader — provided the deal goes through |
Strides Arcolab (Arrow) | Apotex | Share swap giving Strides the controlling interest | To create the leading player in the Australian generics market |
Eli Lilly | ARMO BioSciences | $1.6 billion | To bolster Lilly’s immuno-oncology program |
TapImmune | Marker Therapeutics | A merger-of-equals under which the stockholders of TapImmune and Marker will each own around 50% of the combined company | To add to TapImmune’s pipeline a synergistic portfolio of highly-differentiated T-cell therapies that has demonstrated impressive results in early trials |
Fujifilm Holdings | Remaining stake in Toyama Chemical | Reportedly $549 million to $640 million | To strengthen Fujifilm’s health care arm, offering an alternative revenue stream to the struggling mainstay office equipment business |
Shanghai Pharmaceutical Holding and a fund managed by SFund International Investment Fund Management | Takeda’s 51.34% stake in Guangdong Techpool Bio-Pharma | Approximately $280 million | A divestment to allow Takeda greater focus on its key areas of focus |
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Date: June 06, 2018